The role of mass spectrometry in the analysis of vitamin D compounds

Mass Spectrometry Reviews

Volumn 32, Issue 1, 2013, Pages 72-86

  Gathungu, Rose M ^a   Flarakos, Caroline C ^a   Satyanarayana Reddy, G ^b,c   Vouros, Paul ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b Epimer LLC   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

1 ,25 dihydroxy 3 epi vitamin D3; 1 ,25 dihydroxyvitamin D3; GC MS; LC MS MS; vitamin D analogs

Indexed keywords

ANALYTICAL METHOD; GC-MS; LC-MS/MS; SENSITIVITY AND SPECIFICITY; STRUCTURAL CHARACTERIZATION; VITAMIN-D;

MASS SPECTROMETRY;

VITAMINS;

DRUG DERIVATIVE; VITAMIN D;

ANIMAL; CHEMISTRY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; REVIEW; STATISTICS;

ANIMALS; CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; VITAMIN D;

EID: 84872863014     PISSN: 02777037     EISSN: 10982787     Source Type: Journal    
DOI: 10.1002/mas.21353     Document Type: Review

References (110)

1. Abe E, Miyaura C, et al. 1981. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 78 (8): 4990-4994. (Pubitemid 12225607)
2. Adams JS,. 1989. Vitamin D metabolite-mediated hypercalcemia. Endocrinol Metab Clin North Am 18: 765-778. (Pubitemid 19233015)
3. Adorini L, Penna G,. 2008. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 4: 404-412.
4. Aronov PA, Hall LM, et al. 2008. Metabolic profiling of major vitamin D metabolites using Diels-Alder derivatization and ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 391: 1917-1930.
5. Astecker N, Reddy GS, et al. 2000. 1alpha, 25-Dihydroxy-3-epi-vitamin D3 a physiological metabolite of 1alpha,25-dihydroxyvitamin D3: Its production and metabolism in primary human keratinocytes. Mol Cell Endocrinol 170: 91-101. (Pubitemid 32012583)
6. Beckman MJ, Tadikonda P, et al. 1996. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 35: 8465-8472. (Pubitemid 26240500)
7. Bikle DD, Pillai S,. 1988. Vitamin D metabolite production and function in keratinocytes. Ann NY Acad Sci 548 (Copyright C 2011U S National Library of Medicine): 27-44.
8. Binkley N, Krueger D, et al. 2008. Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab 93: 1804-1808. (Pubitemid 351656521)
9. Blunt JW, DeLuca HF, et al. 1968. 25-Hydroxycholecalciferol. A biologically active metabolite of vitamin D3. Biochemistry 7: 3317-3322.
10. Blunt JW, Tanaka Y, et al. 1968. Biological activity of 25-hydroxycholecalciferol, a metabolite of vitamin D3. Proc Natl Acad Sci USA 61 (Copyright C 2011US National Library of Medicine): 1503-1506.
11. Bouillon R, Eelen G, et al. 2006. Vitamin D and cancer. J Steroid Biochem Mol Biol 102: 156-162. (Pubitemid 44781185)
12. Bouillon R, Okamura WH, et al. 1995. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 16: 200-257.
13. Brown AJ, Ritter CS, et al. 2005. Isolation and identification of 1alpha-hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion. J Cell Biochem 96 (3): 569-578. (Pubitemid 41504654)
14. Brown AJ, Slatopolsky E,. 2008. Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol Aspects Med 29: 433-452.
15. Byrdwell WC, De VJ, et al. 2008. Analyzing vitamin D in foods and supplements: Methodologic challenges. Am J Clin Nutr 88: 554S-557S.
16. Cantorna MT,. 2006. Vitamin D and its role in immunology: Multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol 92: 60-64. (Pubitemid 43831951)
17. Claridge T, editor, 2000. High-resolution NMR techniques in organic chemistry. Pergamon.
18. Clive DR, Sudhaker D, et al. 2002. Analytical and clinical validation of a radioimmunoassay for the measurement of 1,25 dihydroxy vitamin D. Clin Biochem 35: 517-521. (Pubitemid 35462126)
19. Davis CD,. 2008. Vitamin D and cancer: Current dilemmas and future research needs. Am J Clin Nutr 88: 565S-569S.
20. DeLuca HF,. 1967. Mechanism of action and metabolic fate of vitamin D. Vitam Horm (New York) 25: 315-367.
21. Ding S, Schoenmakers I, et al. 2010. Quantitative determination of vitamin D metabolites in plasma using UHPLC-MS/MS. Anal Bioanal Chem 398: 779-789.
22. Duan X, Weinstock-Guttman B, et al. 2010. Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal Chem 82 (Copyright C 2011US National Library of Medicine): 2488-2497.
23. Dusso AS, Brown AJ, et al. 2005. Vitamin D. Am J Physiol Renal Physiol 289 (Copyright C2011US National Library of Medicine): F8-F28. (Pubitemid 40863568)
24. Ersfeld DL, Rao DS, et al. 2004. Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 37: 867-874. (Pubitemid 39209026)
25. Evans RM,. 2005. The nuclear receptor superfamily: A rosetta stone for physiology. Mol Endocrinol 19: 1429-1438. (Pubitemid 41002974)
26. Garland CF, Comstock GW, et al. 1989. Serum 25-hydroxyvitamin D and colon cancer: Eight-year prospective study. Lancet 2 (Copyright C 2011US National Library of Medicine): 1176-1178. (Pubitemid 19275448)
27. Garland CF, Garland FC, et al. 1999. Calcium and vitamin D: Their potential roles in colon and breast cancer prevention. Ann NY Acad Sci 889: 107-119. (Pubitemid 30040430)
28. Giovannucci E,. 2008. Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol 624: 31-42.
29. Glendenning P,. 2003. Issues of standardization and assay-specific clinical decision limits for the measurement of 25-hydroxyvitamin D, comments on. Am J Clin Nutr 77: 522-523. (Pubitemid 36133400)
30. Glendenning P, Noble JM, et al. 2003. Issues of methodology, standardization and metabolite recognition for 25-hydroxyvitamin D when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases. Ann Clin Biochem 40: 546-551. (Pubitemid 37152208)
31. Haussler MR, Haussler CA, et al. 1997. The vitamin D hormone and its nuclear receptor: Molecular actions and disease states. J Endocrinol 154 (Suppl): S57-73.
32. Haussler MR, Whitfield GK, et al. 2011. The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis. Rev Endocr Metab Disord.
33. Higashi T, Miura K, et al. 1999. Usefulness of derivatization in high-performance liquid chromatography/tandem mass spectrometry of conjugated vitamin D metabolites. Anal Sci 15: 619-623.
34. Higashi T, Shibayama Y, et al. 2008. Liquid chromatography-tandem mass spectrometric method for the determination of salivary 25-hydroxyvitamin D3: A noninvasive tool for the assessment of vitamin D status. Anal Bioanal Chem 391: 229-238.
35. Higashi T, Shimada K, et al. 2010. Advances in determination of vitamin D related compounds in biological samples using liquid chromatography-mass spectrometry: A review. J Chromatogr B 878 (20): 1654-1661.
36. Higashi T, Suzuki M, et al. 2011. A specific LC/ESI-MS/MS method for determination of 25-hydroxyvitamin D3 in neonatal dried blood spots containing a potential interfering metabolite, 3-epi-25-hydroxyvitamin D3. J Sep Sci 34 (7): 725-732.
37. Holick MF,. 2003. Vitamin D: A millenium perspective. J. Cell Biochem 88: 296-307.
38. Holick MF,. 2006. Vitamin D: Its role in cancer prevention and treatment. Prog Biophys Mol Biol 92: 49-59. (Pubitemid 43831958)
39. Holick MF,. 2008. Sunlight, UV-radiation, vitamin D and skin cancer: How much sunlight do we need? " Adv Exp Med Biol 624: 1-15.
40. Holick MF,. 2009. Vitamin D status: Measurement, interpretation, and clinical application. Ann Epidemiol 19 (Copyright C 2011US National Library of Medicine): 73-78.
41. Holick MF, MacLaughlin JA, et al. 1980. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 210 (Copyright C2011US National Library of Medicine): 203-205. (Pubitemid 11252464)
42. Holick MF, Schnoes HK, et al. 1971. Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine. Proc Natl Acad Sci USA 68 (Copyright C2011 US National Library of Medicine P 803-L 804).
43. Hollis BW,. 2000. Comparison of commercially available 125I-based RIA methods for the determination of circulating 25-hydroxyvitamin D. Clin Chem (Washington, D.C., U.S.) 46: 1657-1661.
44. Hollis BW,. 2007. Assessment of circulating 25(OH)D and 1,25(OH)2D: Emergence as clinically important diagnostic tools. Nutr Rev 65 (Copyright C 2011US National Library of Medicine): S87-S90.
45. Hosomi J, Hosoi J, et al. 1983. Regulation of terminal differentiation of cultured mouse epidermal cells by 1α,25-dihydroxyvitamin D3. Endocrinology (Baltimore) 113: 1950-1957. (Pubitemid 14213553)
46. Ishigai M, Ishitani Y, et al. 1997. Characteristics of mass spectrometric analyses coupled to gas chromatography and liquid chromatography for 22-oxacalcitriol, a vitamin D3 analog, and related compounds. J Chromatogr B Biomed Sci Appl 704: 11-17. (Pubitemid 28021883)
47. Jones G,. 2010. Vitamin D analogs. Endocrinol Metab Clin North Am 39: 447-472.
48. Jones G, Horst R, et al. 2007. Contemporary diagnosis and treatment of vitamin D-related disorders. J Bone Miner Res 22: V11-V15. (Pubitemid 351304641)
49. Jones G, Prosser DE, et al. 2011. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D. Arch Biochem Biophys.
50. Kamao M, Tatematsu S, et al. 2004. C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-Hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. J Biol Chem 279 (16): 15897-15907. (Pubitemid 38509277)
51. Kamao M, Tatematsu S, et al. 2001. Isolation, identification and biological activity of 24R,25-dihydroxy-3-epi-vitamin D3: A novel metabolite of 24R,25-dihydroxyvitamin D3 produced in rat osteosarcoma cells (UMR 106). J Nutr Sci Vitaminol (Tokyo) 47 (2): 108-115. (Pubitemid 32586090)
52. Kamao M, Tsugawa N, et al. 2007. Quantification of fat-soluble vitamins in human breast milk by liquid chromatography-tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 859: 192-200. (Pubitemid 350046445)
53. Kanis JA,. 1997. Biochemical markers in osteoporosis. Scand J Clin Lab Invest Suppl 227 (Copyright C 2011US National Library of Medicine): 6-11. (Pubitemid 27163391)
54. Kanis JA, McCloskey EV, et al. 1997. Treatment of osteoporosis with vitamin D. Osteoporos Int 7 (Suppl 3Copyright C2011US National Library of Medicine): S140-S146.
55. Kimball SM, Vieth R,. 2007. A comparison of automated methods for the quantitation of serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. Clin Biochem 40: 1305-1310. (Pubitemid 47570041)
56. Kissmeyer AM, Sonne K, et al. 2000. Determination of the vitamin D analog EB 1089 (seocalcitol) in human and pig serum using liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 740: 117-128. (Pubitemid 30160878)
57. Kusudo T, Sakaki T, et al. 2004. Metabolism of A-ring diastereomers of 1α,25-dihydroxyvitamin D3 by CYP24A1. Biochem Biophys Res Commun 321 (4): 774-782. (Pubitemid 39044377)
58. Lai JKC, Lucas RM, et al. 2010. Assessing vitamin D status: Pitfalls for the unwary. Mol Nutr Food Res 54: 1062-1071.
59. Larriba MJ, Valle N, et al. 2008. Vitamin D3 and colorectal cancer. Adv Exp Med Biol 617: 271-280.
60. Liu S, Gupta A, et al. 2007. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 16 (4): 329-335. (Pubitemid 46944331)
61. Luque dCMD, Fernaindez-Romero JM, et al. 1999. Determination of vitamin D3 metabolites: State-of-the-art and trends. J Pharm Biomed Anal 20: 1-17. (Pubitemid 29206579)
62. Masuda S, Kamao M, et al. 2000. Characterization of 3-epi-1α,25- dihydroxyvitamin D3 involved in 1α,25-dihydroxyvitamin D3 metabolic pathway in cultured cell lines. Biol Pharm Bull 23: 133-139. (Pubitemid 30136968)
63. Masuda S, Okano T, et al. 1997. A novel high-performance liquid chromatographic assay for vitamin D metabolites using a coulometric electrochemical detector. J Pharm Biomed Anal 15: 1497-1502. (Pubitemid 27268326)
64. Mathieu C, Adorini L,. 2002. The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med 8: 174-179. (Pubitemid 34297090)
65. Matsumoto K, Azuma Y, et al. 1991. Involvement of endogenously produced 1,25-dihydroxyvitamin D3 in the growth and differentiation of human keratinocytes. Biochim Biophys Acta Mol Cell Res 1092: 311-318.
66. Molnar F, Sigueiro R, et al. 2011. 1alpha, 25(OH)2-3-epi-vitamin D3, a natural physiological metabolite of vitamin D3: Its synthesis, biological activity and crystal structure with its receptor. PLoS ONE 6 (3): e18124.
67. Mucci LA, Spiegelman D,. 2008. Vitamin D and prostate cancer risk-A less sunny outlook? " J Natl Cancer Inst 100 (Copyright C 2011US National Library of Medicine): 759-761. (Pubitemid 351809673)
68. Nagpal S, Na S, et al. 2005. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26: 662-687. (Pubitemid 41127276)
69. Napoli JL, Horst RL,. 1983. (23S)-1,23,25-Trihydroxycholecalciferol, an intestinal metabolite of 1,25-dihydroxycholecalciferol. Biochem J 214: 261-264. (Pubitemid 13070702)
70. Norman AW, Putkey JA, et al. 1982. Intestinal calcium transport: Pleiotropic effects mediated by vitamin D. Fed Proc Fed Am Soc Exp Biol 41: 78-83. (Pubitemid 12138003)
71. Ohnuma N, Bannai K, et al. 1980. Studies on the metabolism of vitamin D. XVII. Isolation of a new metabolite of vitamin D produced in vivo, 1α,25-dihydroxyvitamin D3 26,23-lactone. Arch Biochem Biophys 204: 387-391. (Pubitemid 11186379)
72. Perez A, Raab R, et al. 1996. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 134 (Copyright (C) 2011 American Chemical Society (ACS). All Rights: Reserved.): 1070-1078. (Pubitemid 26183140)
73. Pillai S, Bikle DD, et al. 1988. Vitamin D and epidermal differentiation: Evidence for a role of endogenously produced vitamin D metabolites in keratinocyte differentiation. Skin Pharmacol 1 (Copyright C 2011US National Library of Medicine): 149-160. (Pubitemid 19182388)
74. Plum LA, DeLuca HF,. 2010. Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 9 (12): 941-955.
75. Reddy GS, Muralidharan KR, et al. 2001. Metabolism of 1α, 25-dihydroxyvitamin D3 and its C-3 epimer 1α,25-dihydroxy-3-epi-vitamin D3 in neonatal human keratinocytes. Steroids 66: 441-450. (Pubitemid 32140921)
76. Reddy GS, Muralidharan KR, Okamura WH, Tserng K-Y, McLane JA,. 1994. " Vitamin D a pluripotent steroid hormone: Structural studies, molecular endocrinology and clinical applications., Norman AW, Bouillon R, Thomasset M, editors. De Gruyter. Berlin, Germany. pp 172-173.
77. Reddy GS, Omdahl JL, et al. 2006. 23-carboxy-24,25,26,27-tetranorvitamin D3 (calcioic acid) and 24-carboxy-25,26,27-trinorvitamin D3 (cholacalcioic acid): End products of 25-hydroxyvitamin D3 metabolism in rat kidney through C-24 oxidation pathway. Arch Biochem Biophys 455 (1): 18-30. (Pubitemid 44740089)
78. Reddy GS, Rao DS, et al. 2000. 1α,25-Dihydroxy-16-ene-23-yne- vitamin D3 and 1α,25-dihydroxy-16-ene-23-yne-20-epi-vitamin D3: Analogs of 1α,25-dihydroxyvitamin D3 that resist metabolism through the C-24 oxidation pathway are metabolized through the C-3 epimerization pathway. Arch Biochem Biophys 383: 197-205.
79. Reddy GS, Robinson M, et al. 2007. Removal of C-ring from the CD-ring skeleton of 1α,25-dihydroxyvitamin D3 does not alter its target tissue metabolism significantly. Arch Biochem Biophys 460: 254-261. (Pubitemid 46589390)
80. Reddy GS, Tserng KY,. 1989. Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D3 through the C-24 oxidation pathway. Biochemistry 28: 1763-1769. (Pubitemid 19072051)
81. Reddy GS, Tserng KY, et al. 1987. Isolation and identification 1,23-dihydroxy-24,25,26,27-tetranorvitamin D3, a new metabolite of 1,25-dihydroxyvitamin D3 produced in rat kidney. Biochemistry 26: 324-331. (Pubitemid 17014435)
82. Rehan VK, Torday JS, et al. 2002. 1α,25-Dihydroxy-3-epi-vitamin D3, a natural metabolite of 1α,25-dihydroxy vitamin D3: Production and biological activity studies in pulmonary alveolar type II cells. Mol Genet Metab 76: 46-56.
83. Reichrath J, Perez A, et al. 1997. Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: An immunohistological evaluation. Acta Derm Venereol 77 (Copyright C 2011US National Library of Medicine): 268-272. (Pubitemid 27286457)
84. Reinhardt TA, Napoli JL, et al. 1981. A new in vivo metabolite of vitamin D3: 1,25,26-trihydroxyvitamin D3. Biochem Biophys Res Commun 99: 302-307. (Pubitemid 12243606)
85. Reinhardt TA, Napoli JL, et al. 1981. 1α,25,26-Trihydroxyvitamin D3: an in vivo and in vitro metabolite of vitamin D3. Biochemistry 20: 6230-6235. (Pubitemid 12217943)
86. Rhieu SY, Annalora AJ, et al. 2011. A new insight into the role of rat cytochrome P450 24A1 in metabolism of selective analogs of 1alpha,25- dihydroxyvitamin D. Arch Biochem Biophys 509 (1): 33-43.
87. Roth HJ, Schmidt-Gayk H, et al. 2008. Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann Clin Biochem 45 (Pt 2): 153-159. (Pubitemid 351724586)
88. Sakaki T, Kagawa N, et al. 2005. Metabolism of vitamin D3 by cytochromes P450. Front Biosci 10: 119-134.
89. Seiden-Long I, Vieth R,. 2007. Evaluation of a 1,25-dihydroxyvitamin D enzyme immunoassay. Clin Chem (Washington, D.C., U.S.) 53: 1104-1108. (Pubitemid 46867527)
90. Sekimoto H, Siu-Caldera ML, et al. 1999. 1α,25-Dihydroxy-3-epi- vitamin D3: In vivo metabolite of 1α,25-dihydroxyvitamin D3 in rats. FEBS Lett 448: 278-282. (Pubitemid 29168503)
91. Shah I, James R, et al. 2011. Misleading measures in Vitamin D analysis: A novel LC-MS/MS assay to account for epimers and isobars. Nutr J 10: 46.
92. Shimizu M, Wang X, et al. 1997. Fluorimetric assay of 1α,25-dihydroxyvitamin D3 in human plasma. J Chromatogr B Biomed Appl 690: 15-23. (Pubitemid 27136451)
93. Singh RJ,. 2008. Are clinical laboratories prepared for accurate testing of 25-hydroxy vitamin D? " Clin Chem 54 (Copyright C 2011 US National Library of Medicine): 221-223. (Pubitemid 351182624)
94. Singh RJ, Taylor RL, et al. 2006. C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. J Clin Endocrinol Metab 91 (8): 3055-3061. (Pubitemid 44271755)
95. Siu-Caldera ML, Sekimoto H, et al. 1999. Production of 1α,25-dihydroxy-3-epi-vitamin D3 in two rat osteosarcoma cell lines (UMR 106 and ROS 17/2.8): Existence of the C-3 epimerization pathway in ROS 17/2.8 cells in which the C-24 oxidation pathway is not expressed. Bone (N.Y.) 24: 457-463. (Pubitemid 29234134)
96. Spina CS, Tangpricha V, et al. 2006. Vitamin D and cancer. Anticancer Res 26: 2515-2524. (Pubitemid 44155530)
97. Stumpf WE, Sar M, et al. 1979. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 206 (4423): 1188-1190. (Pubitemid 10159658)
98. Tai SSC, Bedner M, et al. 2010. Development of a candidate reference measurement procedure for the determination of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal Chem (Washington, D.C., U.S.) 82: 1942-1948.
99. Tanaka Y, Deluca HF,. 1971. Bone mineral mobilization activity of 1,25-dihydroxycholecalciferol, a metabolite of vitamin D. Arch Biochem Biophys 146 (Copyright C 2011US National Library of Medicine): 574-578.
100. Terry AH, Sandrock T, et al. 2005. Measurement of 25-hydroxyvitamin D by the Nichols ADVANTAGE, DiaSorin LIAISON, DiaSorin RIA, and liquid chromatography-tandem mass spectrometry. Clin Chem (Washington, D.C., U.S.) 51: 1565-1566. (Pubitemid 41060911)
101. Thorne J, Campbell MJ,. 2008. The vitamin D receptor in cancer. Proc Nutr Soc 67: 115-127. (Pubitemid 351543394)
102. van den Ouweland JM, Beijers AM, et al. 2011. Fast separation of 25-hydroxyvitamin D3 from 3-epi-25-hydroxyvitamin D3 in human serum by liquid chromatography-tandem mass spectrometry: Variable prevalence of 3-epi-25-hydroxyvitamin D3 in infants, children, and adults. Clin Chem 57 (11): 1618-1619.
103. Vieth R,. 1990. The mechanisms of vitamin D toxicity. Bone Miner 11: 267-272. (Pubitemid 20377665)
104. Vogeser M,. 2010. Quantification of circulating 25-hydroxyvitamin D by liquid chromatography-tandem mass spectrometry. J Steroid Biochem Mol Biol 121 (3-5): 565-573.
105. Walters MR,. 1995. Newly identified effects of the vitamin D endocrine system: Update 1995. Endocr Rev Monogr 4: 47-56.
106. Yeung B, Vouros P,. 1995. The role of mass spectrometry in vitamin D research. Mass Spectrom Rev 14: 179-194.
107. Yeung B, Vouros P, et al. 1994. Derivatization of vitamin D metabolites for analysis by capillary HPLC-tandem mass spectrometry. Am Lab (Shelton, Conn.) 26: 12, 14-16.
108. Yeung B, Vouros P, et al. 1993. Characterization of vitamin D3 metabolites using continuous-flow fast atom bombardment tandem mass spectrometry and high-performance liquid chromatography. J Chromatogr 645: 115-123. (Pubitemid 23245452)
109. Yeung B, Vouros P, et al. 1995. Characterization of the metabolic pathway of 1,25-dihydroxy-16-ene vitamin D3 in rat kidney by online high performance liquid chromatography-electrospray tandem mass spectrometry. Biochem Pharmacol 49: 1099-1110.
110. Zerwekh JE,. 2008. Blood biomarkers of vitamin D status. Am J Clin Nutr 87: 1087S-1091S. (Pubitemid 351549268)